Impacto del plan AUGE en el tratamiento de pacientes con infarto agudo al miocardio con supradesnivel ST, en hospitales chilenos
Artículo
Open/ Download
Publication date
2008-07Metadata
Show full item record
Cómo citar
Nazzal Nazal, Carolina
Cómo citar
Impacto del plan AUGE en el tratamiento de pacientes con infarto agudo al miocardio con supradesnivel ST, en hospitales chilenos
Author
Abstract
In 2005 the Chilean government started a health care reform (AUGE)
that guarantees medical treatment for acute myocardial infarction. Aim: To quantify
the impact ofAUGE on the management and inhospital mortality of STEMI in a group of
Chilean hospitals. Material and methods: Three thousand five hundred and forty six
patients with STEMI from 10 hospitals that perform thrombolysis as the main
reperfusion therapy were analyzed. We compared demographic and clinical
characteristics, hospital treatments and revascularization proceduresin two periods:
regression was used to assess inhospital mortality according to AUGE in the entire
sample and stratified by risk groups. Results: We found no differences in demographic
and clinical characteristics between the two groups. During AUGE threre was a
significant increase in the use of thrombolysis (50% to 60.5%), which was associated
to an increase of hypotension from 29% to 35% (p <0.02) and minor bleedings, from
1.6% to 3.4% (p <0.001). After A UGE there was a significant increase in the use of
beta blockers (65% to 75%), angiotensin converting enzyme inhibitors (70% to 76%),
statins (48% to 58%), and aspirin (96% to 97.5%) (p <0.05). Global inhospital
mortality decreased from 12.0% to 8.6% (p <0.003) and from 10.6% to 6.8% (p
<0.005) in patients treated with thrombolytics. The adjusted odds ratio for inhospital
mortality comparing after and before AUGE, was 0.64 (IC 95%, 0,47-0.86).
Conclusions: The implementation of AUGE has been successful in reducing inhospital
mortality of STEMI This has been achieved through a better use of evidence based
medicine and reperfusion strategies .
Patrocinador
Fuente de apoyo financiero: Sociedad Chilena de Cardiología y Cirugía Cardiovascular y
Laboratorios Bayer de Chile. Ambas instituciones no tuvieron influencia en el diseño y
conducción del estudio
Quote Item
Rev. méd. Chile, v.136, n.10, p. 1231-1239, oct. 2008
Collections